Lufax Holding Ltd vs TG Therapeutics Inc — how do they compare? Lufax Holding Ltd trades at $1.54 (market cap $2.41B), while TG Therapeutics Inc trades at $49.62 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 3.2× Lufax Holding Ltd's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.
| LU | TGTX | |
|---|---|---|
Market Cap | $2.41B | $7.64B |
Sector | Technology | Health |
52-Week High | $4.40 | $59.06 |
52-Week Low | $1.23 | $26.94 |
Enterprise Value | — | $7.84B |
Signals from Pluang's Aura AI — not financial advice
Lufax Holding Ltd (LU) trades at $1.525, down 8.13% today, showing significant volatility. The stock presents a mixed picture with bullish technical signals but concerning fundamentals, including negative profitability metrics with a -9.08% net income margin and -2.6% ROE. Recent management changes and ongoing securities class action lawsuits create uncertainty, though analyst consensus remains predominantly positive with 69% buy ratings.
The outlook remains cautious due to persistent losses and legal challenges, though attractive valuation multiples (P/S 0.39, P/B 0.11) suggest potential upside if operational improvements materialize. Key risks include execution challenges in China's financial services sector and resolution of investor litigation.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Trailing returns across standard periods
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →